title: Effects of fructo-oligosaccharides ingestion on fecal bifidobacteria and selected metabolic indexes of colon carcinogenesis in healthy humans.
abstract: Fructo-oligosaccharides (FOS) are a mixture of oligosaccharides consisting of glucose linked to fructose units. They are not digested in the human small intestine but fermented in the colon, where they could specifically promote the growth of some species of the indigenous microflora, especially bifidobacteria. We assessed in healthy humans the effects of FOS ingestion in fecal bifidobacteria and selected metabolic indexes potentially involved in colonic carcinogenesis. Twenty volunteers randomly divided into two groups were studied for three consecutive 12-day periods. During the ingestion period, they received 12.5 g/day FOS or placebo (saccharose) in three oral doses. Stools were regularly collected and analyzed. FOS ingestion led to an increase in fecal bifidobacterial counts [7.9 +/- 0.5 to 9.1 +/- 0.3 (SE) log colony-forming units/g wet wt, p < 0.01] and beta-fructosidase activity (9.6 +/- 1.9 to 13.8 +/- 1.9 IU/g dry wt, p < 0.01). In contrast, FOS ingestion had no significant effect on fecal total anaerobes, pH, the activities of nitroreductase, azoreductase, and beta-glucuronidase, and the concentrations of bile acids and neutral sterols. We conclude that ingestion of FOS, at a clinically tolerated dose of 12.5 g/day, led to an increase in colonic bifidobacteria. This effect was not associated in healthy humans with beneficial changes in various factors potentially involved in the pathogenesis of colonic cancer.
authors.affiliation: Hôpital Saint-Lazare, Institut National de la Santé et de la Recherche Médicale, Paris, France.
authors.forename: Y
authors.initials: Y
authors.lastname: Bouhnik
authors.forename: B
authors.initials: B
authors.lastname: Flourié
authors.forename: M
authors.initials: M
authors.lastname: Riottot
authors.forename: N
authors.initials: N
authors.lastname: Bisetti
authors.forename: M F
authors.initials: MF
authors.lastname: Gailing
authors.forename: A
authors.initials: A
authors.lastname: Guibert
authors.forename: F
authors.initials: F
authors.lastname: Bornet
authors.forename: J C
authors.initials: JC
authors.lastname: Rambaud
mesh_terms: D000328:Adult; D001644:Bifidobacterium / Q000187:drug effects* / Q000201:enzymology / Q000254:growth & development; D001647:Bile Acids and Salts / Q000378:metabolism; D003110:Colonic Neoplasms / Q000378:metabolism*; D005243:Feces / Q000382:microbiology*; D005260:Female; D005632:Fructose / Q000008:administration & dosage / Q000494:pharmacology*; D005966:Glucuronidase / Q000378:metabolism; D006026:Glycoside Hydrolases / Q000378:metabolism; D006801:Humans; D006863:Hydrogen-Ion Concentration; D008297:Male; D009247:NADH, NADPH Oxidoreductases / Q000378:metabolism; D009601:Nitroreductases / Q000378:metabolism; D009844:Oligosaccharides / Q000008:administration & dosage / Q000494:pharmacology*; D010919:Placebos; D013261:Sterols / Q000378:metabolism; D043324:beta-Fructofuranosidase
chemical_list: D001647:Bile Acids and Salts; D009844:Oligosaccharides; D010919:Placebos; D013261:Sterols; D005632:Fructose; D009247:NADH, NADPH Oxidoreductases; D009601:Nitroreductases; C021106:azoreductase; D006026:Glycoside Hydrolases; D043324:beta-Fructofuranosidase; D005966:Glucuronidase